Prescribing information

 

Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.

Hear UK-based rheumatology experts critically assess the latest clinical trial and case-study evidence supporting Cosentyx treatment, and the priorities for improving patient management.

 

 

Click here for Cosentyx® (secukinumab) prescribing information

In this webinar, watch UK-based rheumatology and dermatology experts Professor Miriam Wittmann and Dr Helena Marzo-Ortega discuss the importance of joint plaque psoriasis (PsO) and psoriatic arthritis (PsA) clinics and offer perspectives on how joint dermatology-rheumatology clinics can be established within a Trust and what benefits they can offer.

To watch the webinar, click on the recording above. We look forward to sharing more videos throughout the year.

 

 

Click here for Cosentyx® (secukinumab) prescribing information

In this webinar, Dr Christos Kasparis and Professor Laura Coates discuss the management of patients with PsO and PsA with multiple manifestations and offer perspectives on the importance of timely screening and treating appropriate patients early with the right biologic. The opinion leaders also describe the Complete Cosentyx (secukinumab) Approach*, discussing clinical trial evidence from MAXIMISE for PsA, and nail and scalp data.

To watch the webinar, click on the recording above. We look forward to sharing more videos throughout the year.

 

 

Click here for Cosentyx® (secukinumab) prescribing information

What is the evidence supporting IL-17A inhibition as a valuable therapy strategy across the spectrum of PsA and axSpA (AS and nr-axSpA) disease?

Using our new ‘on-demand’ webinar format, hear UK-based rheumatology experts critically assess the latest clinical trial and case-study evidence supporting Cosentyx treatment and the priorities for improving patient management.

To watch the webinar, click on the recording above. You can either view the whole event or choose the presentation you want to watch by skipping ahead to the start times listed below. We look forward to sharing more videos throughout the year.

Start time Speaker   Title and content
00:00 Chair: Paul Emery

 
Introduction
Prof. Paul Emery introduces the faculty, agenda and objectives of the webinar
06:52 Bruce Kirkham

 
EXCEED: IL-17A versus TNF inhibition in PsA
Prof. Bruce Kirkham examines the outcomes of EXCEED, a head-to-head trial of two biologics with different modes of action, that may help guide clinical decision making in PsA
16:55 Laura Coates

 
MAXIMISE: Improving patient outcomes in axial PsA
Dr Laura Coates highlights the clinical importance of the often underrepresented axial PsA manifestation, and through the use of a case study, explores Cosentyx data from MAXIMISE, the first large randomised-controlled trial in axial PsA
30:32 Raj Sengupta

 
PREVENT: New insights in nr-axSpA
Cosentyx has already demonstrated long-term efficacy and safety evidence in AS. During this presentation Dr Raj Sengupta examines how improved clinical and imaging outcomes, demonstrated in the PREVENT study, provided the basis for the recent approval of Cosentyx in nr-axSpA
39:04   All

 
Panel discussion
Prof. Paul Emery moderates the panel discussion that concludes the session

 

Arrow with the text explore the best content from 2020. Click to find out more

Arrow with the text Why Cosentyx in PsA? Click to find out more

Arrow with the text Why Cosentyx in axSpA? Click to find out more

*The Complete Cosentyx Approach is defined as efficacy in both skin and persistent nail and scalp psoriasis, as well as psoriatic arthritis, and improvements in quality of life.

AS, ankylosing spondylitis; axSpA, axial spondyloarthritis; BSR, British Society for Rheumatology; DMARD, disease-modifying antirheumatic drug; EULAR, European League Against Rheumatism; IL, interleukin; MRI, magnetic resonance imaging; nr-axSpA, non-radiographic axial spondyloarthritis; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis; RCT, randomised controlled trial.

Rate this content: 
No votes yet
UK | June 2021 | 131165
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]